Ziyi Li, Ph.D.
Department of Biostatistics, Division of Discovery Science
About Dr. Ziyi Li
My research sits at the intersection of statistics, high-throughput biomedical data, and oncology data science, and is motivated by the close interplay between pressing clinical questions and advances in computational biology. I develop statistical and computational methods for complex data generated from spatial omics, single-cell profiling, and other multi-omics platforms, with a particular focus on multi-omics integration, 3D tissue reconstruction, and cell–cell interaction analysis. More broadly, I am interested in creating adaptive and interpretable analytic frameworks that can extract biologically meaningful insights from complex tumor ecosystems and support precision oncology.
A central theme of my work is translating methodological innovation into real biomedical and clinical applications. I have collaborated with multidisciplinary teams in leukemia, breast cancer, lymphoma, radiation oncology, and cellular therapy, contributing to studies of novel therapeutics, tumor evolution, and personalized treatment strategies. I have also provided statistical leadership and support for MD Anderson SPORE projects in brain and prostate cancer, as well as for the Data Coordination Center of the NCI TBEL (Translational and Basic Science Research in Early Lesion) Research Consortia.
I currently serve as PI on an NIGMS R35 focused on cell–cell interaction analysis in spatial transcriptomics and has received an NCI R01 on cellular deconvolution in lung cancer. In addition, I serve as an Associate Editor for Biostatistics, Biometrics, and the American Journal of Neuroradiology, and I actively review for NIH, DoD, and international funding agencies. Personal website: https://ziyili20.github.io/
Present Title & Affiliation
Primary Appointment
Adjunst Assistant Professor, Department of Biostatistics, Division of Discovery Science, The University of Texas Health Center, Houston, Texas
Adjunct Assistant Professor, Department of Statistics, Rice University, Houston, TX
Assistant Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Adjunct Assistant Professor, Department of Biostatistics and Data Science, UT Health School of Public Health, Houston, Texas
Adjunct Assistant Professor, Department of Statistics, Rice University, Houston, TX
Assistant Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
My research interest is to develop useful statistical tools for the analyses of genomic, multi-omics and electronic health record data. In addition to methodology research, I am also interested in collaboration projects with Biologist and Physicians. My previous collaboration project involves the study of cancer, Alzheimer's disease, autism, obesity and cardiovascular diseases. Keywords: High-throughput data analysis; Bioinformatics; Biomarker analysis; Multi-omics; Single cell data analysis
Education & Training
Degree-Granting Education
| 2018 | Emory University, Atlanta, Georgia, US, Biostatistics, Ph.D |
| 2014 | Yale University, New Haven, Connecticut, US, Biostatistics, MPH |
| 2012 | Peking University, Beijing, CN, Statistics, BS |
Postgraduate Training
| 2018-2020 | Postdoctoral Fellow, Biostatistics and Bioinformatics, Emory University, Atlanta, Georgia |
Experience & Service
Other Professional Positions
Postdoctoral Researcher, Emory University, Atlanta, GA, 2018 - 2020
Graduate Research Assistant, Emory University, Atlanta, GA, 2015 - 2018
Graduate Research Assistant, Yale University, Lab for meningioma tumor research, West Haven, CT, 2013 - 2014
Intramural Institutional Committee Activities
Standing member, GSBS Curriculum Committee, The University of Texas MD Anderson Cancer Center, 2023 - 2024
Statistical Reviewer, Scientific Reviewer Committee-3, The University of Texas MD Anderson Cancer Center, 2022 - Present
Committee member, MDA Department of Biostatistics Visiting Guest Lecture Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Reviewer, MD Anderson Cancer Center Multidisciplinary Research Program (MRP) Review Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Extramural Institutional Committee Activities
Committee member, Eastern North American Region International Biometric Society (ENAR) Regional Advisory Board (RAB) Committee, International Biometric Society, 2024 - Present
Committee member, Eastern North American Region International Biometric Society (ENAR) Distinguished Student Paper Award Committee, International Biometric Society, 2023 - Present
Committee member, American Statistical Association (ASA) Mental Health Statistics Section Student Paper Award Committee, American Statistical Association, 2023 - Present
Editorial Activities
Senior Editor, AJNR. American journal of neuroradiology, 2024 - Present
Associate Editor, Journal of applied statistics, 2021 - Present
Honors & Awards
| 2020 | 2nd place of Young Scientist's Excellence Award, MidSouth Computational Biology and Bioinformatics Society Conference |
| 2018 | The Penina and Michael Haber Award, Emory University |
| 2018 | 2nd Place Poster Award, Georgia Statistics Day |
| 2018 | ENAR Poster Award, Eastern North American Region |
| 2016 | Student Paper Award, International Chinese Statistical Association Applied Statistics Symposium |
| 2016 | 2nd Place Prize Award at NSF/ Anderson Student Poster Competition and Boyd Harshbarger Travel Award, Southern Regional Council on Statistics Summer Research Conference |
| 2012 | Scholarship for Excellent Oversea Students, China Selection Inc |
| 2011 | National Innovation Research Funds for Undergraduate, Chinese Ministry of Education |
| 2010 | Winner Prize, Peking University |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2021. Dissecting cell type-specific signals from heterogeneous samples. Invited. Precision Medicine Series Seminar. Houston, Texas, US.
National Presentations
- 2025. A novel statistical method to delineate spatially heterogeneous cell-cell interactions in pancreatic cancer. Invited. Joint Statistical Meeting (JSM). Nashville, TN, US.
- 2025. Accurate Imputation of Pathway-specific Gene Expression in Spatial Transcriptomics with PASTA. Invited. MidSouth Computational Biology and Bioinformatics Society (MCBIOS) Spring Meeting. Salt Lake City, Utah, US.
- 2025. Accurate Imputation of Pathway-specific Gene Expression in Spatial Transcriptomics with PASTA. Invited. Eastern North American Region International Biometric Society (ENAR). New Orlean, LA, US.
- 2023. A Novel Bayesian Model for Assessing Intratumor Heterogeneity of Tumor Infiltrating Leukocytes with Multi-region Gene Expression Sequencing. Invited. Joint Statistical Meeting (JSM). Toronto, Ontario, CA.
- 2023. Advances in statistical methods for studying cellular heterogeneity in genomics data. Invited. WNAR. Anchorage, AK, US.
- 2023. Accommodating time-varying heterogeneity in risk estimation under the Cox model: a transfer learning approach. Invited. Lifetime Data Science Conference (LiDS). Raleigh, NC, US.
- 2023. Identifying novel cells in annotating single-cell RNA-seq data. Invited. Eastern North American Region International Biometric Society (ENAR). Nashville, TN, US.
- 2022. Identifying novel cells in annotating single-cell RNA-seq data. Conference. Joint Statistical Meeting (JSM). Washington, DC, US.
- 2022. Identifying novel cells in annotating single-cell RNA-seq data. Invited. Biostatistics Epidemiology Research Design (BERD) Seminar. Houston, T, US.
- 2021. Short Course: The Analysis of Single-cell RNA Seq Data. Invited. ENAR. Virtual, US.
- 2021. Dissecting cell type-specific signals from heterogeneous samples. Invited. Precision Medicine Series Seminar. Houston, TX, US.
- 2020. Robust partial reference-free composition estimation from tissue expression profile. Invited. International Chinese Statistical Association Applied Statistics Symposium (ICSA). Virtual, US.
- 2020. Robust partial reference-free composition estimation from tissue expression profile. Invited. MidSouth Computational Biology and Bioinformatics Society (MCBIOS) Spring Meeting. Virtual, US.
- 2020. Dissecting cell type-specific signals from heterogeneous samples. Invited. Cleveland, OH, US.
International Presentations
- 2023. Accommodating time-varying heterogeneity in risk estimation under the Cox model: A transfer learning approach. Invited. Computational and Methodology Statistics (CM-Statistics). Berlin, DE.
Formal Peers
- 2023. Accurate identification of locally aneuploid cells by incorporating cytogenetics information in single-cell data analysis. Invited. Philadelphia, PA, US.
- 2022. Identifying novel cells in annotating single-cell RNA-seq data. Invited. Houston, TX, US.
- 2021. Analysis of single cell RNA-seq data. Houston, TX, US.
- 2021. Dissecting cell type-specific signals from heterogeneous samples. Invited. Virtual, US.
Grant & Contract Support
| Date: | 2026 - 2028 |
| Title: | Addressing Unmeasured Covariates in Source Cohorts with Transfer Learning for Survival Outcomes |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R21CA312466 |
| Date: | 2025 - 2030 |
| Title: | Statistical methods to delineate the spatial and temporal pattern of cell-cell interactions in Spatial Transcriptomics data |
| Funding Source: | NIGMS |
| Role: | PI |
| ID: | R35GM159819 |
| Date: | 2025 - 2028 |
| Title: | LC240079 The Role of Intra-Tumor Heterogeneity in Lung Cancer Recurrence and Resistance to Immunotherapy |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| ID: | LC240079 |
| Date: | 2025 - 2030 |
| Title: | ncRNA-targeted therapeutics for triple-negative breast cancer |
| Funding Source: | Houston Methodist Research Institute |
| Role: | Co-I |
| ID: | FP00023370 |
| Date: | 2025 - 2027 |
| Title: | Computerized Platform for Characterizing Tumor Clonal Evolution and Predicting Treatment Prognosis in Myelodysplastic Syndrome |
| Funding Source: | NATIONAL CANCER INSTITUTE |
| Role: | PD/PI |
| ID: | R21CA284094 |
| Date: | 2025 - 2030 |
| Title: | Dissect the consequences of telomere stress on hematopoietic stem cells |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Co-I |
| ID: | GRANT14165041 |
| Date: | 2025 - 2030 |
| Title: | Extracellular nucleic acids in trauma innate immunity |
| Funding Source: | University of Maryland - Baltimore |
| Role: | Principal Investigator-MDACC |
| ID: | #TBA |
| Date: | 2025 - 2028 |
| Title: | Combining FLASH-RT with oxygen-modifying drugs to treat pancreatic cancer |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Advisor |
| ID: | #TBA |
| Date: | 2025 - 2027 |
| Title: | Enabling Differential Expression Analysis with In Silico Perturbation Models: New Methodology and Rigorous Testing |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2025 - 2030 |
| Title: | Innovative RNA-based tumor suppressor nanotherapeutics for deadly cancers |
| Funding Source: | METHODIST HOSPITAL RESEARCH INSTITUTE |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2025 - 2030 |
| Title: | Regulation of Mitochondrial Respiration in Diabetic Kidney Disease |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | Co-I |
| ID: | R01DK142664 |
| Date: | 2025 - 2030 |
| Title: | New statistical methods to delineate spatially heterogeneous cell-cell interactions in pancreatic and gastric cancer |
| Funding Source: | NATIONAL INSTITUTES OF HEALTH |
| Role: | PD/PI |
| ID: | #TBA |
| Date: | 2025 - 2026 |
| Title: | Metabolic reprograming of the Tumor Microenvironment to enhance Natural Killer cell therapy against Osteosarcoma |
| Funding Source: | Texas Academy of Medicine, Engineering, Science and Technology |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2025 - 2028 |
| Title: | Novel tumor suppressive RNA therapeutics for Aggressive Cancers |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP250364 |
| Date: | 2025 - 2028 |
| Title: | Targeting nucleoside metabolism and anti-apoptotic mechanisms in high risk CMML |
| Funding Source: | CANCER PREVENTION RESEARCH INST OF TX |
| Role: | Co-I |
| ID: | RP250341 |
| Date: | 2025 - 2025 |
| Title: | Targeting MEK and FAK signaling in high risk RAS-mutant chronic myelomonocytic leukemia |
| Funding Source: | ELSA U PARDEE FOUNDATION |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2025 - 2027 |
| Title: | microRNA theranostics in Rare Melanomas and in Prevention of Melanoma Metastasis |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| ID: | GRANT14237514 |
| Date: | 2025 - 2028 |
| Title: | Innovative RNA therapeutics for Triple Negative Breast Cancer |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| ID: | GRANT14227418 |
| Date: | 2024 - 2027 |
| Title: | Understanding Racial Disparities in Triple-Negative Breast Cancer Through Extracellular microRNAs |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| ID: | GRANT14158451 |
| Date: | 2024 - 2026 |
| Title: | Feasibility of Combined Genomics/Transcriptomics/scRNA seq (multi-omics assay) for lymphoma microenvironment(LME) Subtyping for Patients with Follicular Lymphoma (FL) |
| Funding Source: | Bristol Myers Squibb Foundation |
| Role: | Co-I |
| ID: | FP00022565 |
| Date: | 2024 - 2029 |
| Title: | SPORE in Brain Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | P50CA127001 |
| Date: | 2024 - 2029 |
| Title: | Targeting NK cell dysfunctions to overcome immune escape in early stage myelodysplastic syndromes |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2024 - 2026 |
| Title: | Dissecting the molecular mechanisms underlying myeloid malignancies induced by U2AF1 mutations in patients with telomere biology disorders |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2024 - 2026 |
| Title: | Development of model systems for the validation of biomarkers of clonal evolution in telomere biology disorders |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2024 - 2028 |
| Title: | Novel RNA therapeutics for peritoneal carcinomatosis from digestive cancers |
| Funding Source: | Seoul National University Hosp |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2024 - 2027 |
| Title: | Estrogen controlled extracellular vesicle microRNAs regulation of breast cancers tumor microenvironment: mechanistic and translational insights |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| ID: | HT942524BCRPEA |
| Date: | 2024 - 2029 |
| Title: | An Integrated Multi-Analyte 3-D Precancer Atlas of the Pancreas for Characterizing Progression to Invasive Neoplasia |
| Funding Source: | UNIV OF PITTSBURGH MEDICAL CTR |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2024 - 2029 |
| Title: | Novel statistical methods for zonal effect analysis of spatial multi-omics data |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | #TBA |
| Date: | 2024 - 2029 |
| Title: | ncRNA-Targeted therapeutics for Triple Negative breast cancer |
| Funding Source: | Houston Methodist Research Institute |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2024 - 2025 |
| Title: | EMOncOpedia: open access oncologic emergency medicine curriculum - pilot module |
| Funding Source: | Society for Academic Emergency Medicine Foundation |
| Role: | Other Significant Contributor |
| ID: | #TBA |
| Date: | 2024 - 2029 |
| Title: | Targeting clonal cytopenias of undetermined significance to overcome myelodysplastic syndrome development |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2024 - 2026 |
| Title: | Aptamer-siRNA chimera Targeted Therapy of Pediatric Medulloblastoma |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2024 - 2029 |
| Title: | The Role of Intra-Tumor Heterogeneity in Lung Cancer Recurrence and Resistance to Immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2024 - 2029 |
| Title: | Metabolic reprogramming of the tumor microenvironment to enhance NK cell therapy against Osteosarcoma |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2024 - 2029 |
| Title: | Ferroptosis-based Therapy in Acute Myeloid Leukemia |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| ID: | #TBA |
| Date: | 2024 - 2029 |
| Title: | Epidemiology of Lymphomas in Latin America (ELLA) |
| Funding Source: | NIH/NCI |
| Role: | Other Significant Contributor |
| ID: | 1R01 CA288469 |
| Date: | 2024 - 2027 |
| Title: | Therapeutic vulnerabilities and predictors of response to chemo(immuno)therapy in patients with high-risk, early stage triple-negative breast cancer (TNBC) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP240293 |
| Date: | 2024 - 2028 |
| Title: | RP240150: Aptamer-siRNA Chimeras Targeted Therapy of Pediatric Medulloblastoma |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2024 - 2027 |
| Title: | RP240029 Characterizing clonal evolution in MDS patients with HMA failure using longitudinal sequencing data and novel computational methods |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PD/PI |
| ID: | RP240029 |
| Date: | 2024 - 2027 |
| Title: | Targeting Ferroptosis Resistance Induced by Mesenchymal Stem Cells in Acute Myeloid Leukemia Leukemia |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2024 - 2027 |
| Title: | Parameter optimization of FLASH radiotherapy to maximize tumor control and minimize normal tissue toxicity |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP240265 |
| Date: | 2024 - 2027 |
| Title: | The Evolution of Intratumor Heterogeneity of Lung Cancers With or Without Immunotherapy and Its Impact on Patient Survival |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP240112 |
| Date: | 2024 - 2027 |
| Title: | BC230435: ncRNA therapy for Triple Negative Breast Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2024 - 2024 |
| Title: | Metabolic reprogramming of the tumor microenvironment to enhance NK cell therapy against Osteosarcoma |
| Funding Source: | ELSA U PARDEE FOUNDATION |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2024 - 2026 |
| Title: | PC230419 The role of androgens in regulating extracellular vesicle secretion and molecular cargo loading by prostate cancer cells |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2023 - 2028 |
| Title: | Precompetitive Collaboration on Liquid Biopsy for Early Cancer Assessment: Data Management and Coordinating Unit |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1U24CA288178-01 |
| Date: | 2023 - 2026 |
| Title: | BC230236 Understanding racial disparities in triple negative breast cancer through extracellular microRNAs |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2023 - 2026 |
| Title: | Targeting Immune-checkpoint protein B7-H3 in Acute Myeloid Leukemia |
| Funding Source: | Department of Defense (DOD) |
| Role: | Biostatistician |
| ID: | RA220172 |
| Date: | 2023 - 2027 |
| Title: | Immune Determinants of Therapy Resistance and Relapse in Acute Myeloid Leukemia |
| Funding Source: | Department of Defense (DOD) |
| Role: | Biostatistician |
| ID: | #TBA |
| Date: | 2023 - 2025 |
| Title: | Targeting Ganglioside GD2 in Triple-negative Breast Cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Biostatistician |
| ID: | BC221281 |
| Date: | 2023 - 2026 |
| Title: | Develop novel therapeutic approaches to prevent the progression of clonal cytopenia of undetermined significance to myelodysplastic syndromes |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2023 - 2026 |
| Title: | Investigating the Role of GD3 Synthase in Immune Suppression and Mutant-p53 Mediated Oncogenesis |
| Funding Source: | Department of Defense (DOD) |
| Role: | Biostatistician |
| ID: | BC221278 |
| Date: | 2023 - 2026 |
| Title: | Targeting Ferroptosis and Mitochondrial Pathways in Acute Myeloid Leukemia |
| Funding Source: | Department of Defense (DOD) |
| Role: | Biostatistician |
| ID: | #TBA |
| Date: | 2023 - 2028 |
| Title: | Study of a REST-context specific therapeutic vulnerability in DIPG |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| ID: | 1R01CA285728-01 |
| Date: | 2023 - 2027 |
| Title: | BC220820: The SIK2 Inhibitor GRN-300 Enhances Olaparib Sensitivity and PD-L1 expression in triple-negative breast cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | BC220820 |
| Date: | 2023 - 2028 |
| Title: | Individual-specific Reference Panel Recovery to Improve Cell-type-specific Inference |
| Funding Source: | NIH subaward via Case Western Reserve University |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2023 - 2026 |
| Title: | Synergistic Induction of Ferroptosis and Mitochondrial Cell Death in Acute Myeloid Leukemia |
| Funding Source: | Department of Defense (DOD) |
| Role: | Biostatistician |
| ID: | #TBA |
| Date: | 2023 - 2028 |
| Title: | Development of Tumor Suppressive Therapy for Co-targeting Oncogenic EF2K/AXL signaling |
| Funding Source: | Houston Methodist Research Institute |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2023 - 2025 |
| Title: | Metabolic reprogramming of the Tumor Microenvironment to enhance NK cell therapy against Osteosarcoma |
| Funding Source: | Osteosarcoma Institute |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2023 - 2024 |
| Title: | Real-Work Outcomes in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma |
| Funding Source: | Mayo Clinic |
| Role: | Co-I |
| ID: | Research Grant Agreement |
| Date: | 2023 - 2026 |
| Title: | Arming NK Cells to Target B7-H3+ AML Cells |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Biostatistician |
| ID: | #TBA |
| Date: | 2023 - 2028 |
| Title: | Whole-Organ Spatial and Time Modeling of Mucosal Field Effects Initiating Bladder Carcinogenesis |
| Funding Source: | William Marsh Rice University |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2023 - 2028 |
| Title: | Targeting Immune-checkpoint Protein B7-H3 in Acute Myeloid Leukemia |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| ID: | 1R01CA283558-01 |
| Date: | 2023 - 2026 |
| Title: | Inhibition of MCL1 in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia After Failure of Hypomethylating Agents |
| Funding Source: | CONQUER CANCER FOUNDATION |
| Role: | Other Professional |
| ID: | #TBA |
| Date: | 2023 - 2025 |
| Title: | Computerized platform for characterizing tumor clonal evolution and predicting treatment prognosis in Myelodysplastic syndrome |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R21CA284097-01 |
| Date: | 2023 - 2028 |
| Title: | Investigation of the molecular/immune cascade underlying evolution of intra-tumor heterogeneity during lung cancer progression and metastasis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA282093-01 |
| Date: | 2023 - 2028 |
| Title: | MD Anderson SPORE in KRASG12C |
| Funding Source: | NIH/NCI |
| Role: | Biostats & Bioinformatics Core Co-investigator |
| ID: | 1P50CA281788-01 |
| Date: | 2023 - 2028 |
| Title: | Computational Methods for Single Cell and Spatial Omics Data to Decipher Tissue Microenvironment |
| Funding Source: | NIH/NIGMS |
| Role: | PI |
| ID: | 1R35GM150403-01 |
| Date: | 2023 - 2026 |
| Title: | Therapeutic Induction of Ferroptosis in Therapy-Resistant AML |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Biostatistician |
| ID: | #TBA |
| Date: | 2023 - 2028 |
| Title: | Coordinating and Data Management Center for Cancer Adoptive Cellular Therapy Network |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1U24CA283562-01 |
| Date: | 2023 - 2026 |
| Title: | Targeting the EIF2AK1 signaling pathway to overcome anemia in myelodysplastic syndromes with ringed sideroblasts and SF3B1 mutations |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2023 - 2024 |
| Title: | Novel anti-B7-H3 Antibody-based Immunotherapy for Acute Myeloid Leukemia |
| Funding Source: | Siddhi Therapeutics, Inc |
| Role: | Biostatistician |
| ID: | #TBA |
| Date: | 2023 - 2027 |
| Title: | REST-SETDB1 in DIPG |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2023 - 2028 |
| Title: | MODELING OF BLADDER CANCER EVOLUTION FROM MUCOSAL FIELD EFFECTS ON THE WHOLE-ORGAN SCALE |
| Funding Source: | National Science Foundation (NSF) |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2023 - 2025 |
| Title: | Individual Specific Gene Expression Referencing Improves Cell-Type Specific Analysis in Bulk RNA-seq Data |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2023 - 2026 |
| Title: | Novel anti-B7-H3 Antibody-based Immunotherapy for Acute Myeloid Leukemia |
| Funding Source: | Subaward-Subcontract via Siddhi Therapeutics, Inc |
| Role: | Biostatistician |
| ID: | GRANT13707016 |
| Date: | 2023 - 2028 |
| Title: | Role of WWOX loss-of-function in progressive cerebellar ataxia and neurodegeneration |
| Funding Source: | NIH/NINDS |
| Role: | Co-I |
| ID: | 1R01NS131970-01 |
| Date: | 2023 - 2025 |
| Title: | Study of Kdm7a in Medulloblastoma |
| Funding Source: | NIH/NINDS |
| Role: | Co-I |
| ID: | 1R21NS131899-01 |
| Date: | 2023 - 2028 |
| Title: | Ferroptosis-based Therapy in Acute Myeloid Leukemia |
| Funding Source: | NIH/NCI |
| Role: | Bioinformatics |
| ID: | 1R01CA279999-01 |
| Date: | 2023 - 2028 |
| Title: | Overcoming T-cell exhaustion by demethylation of TIM3 3’UTR |
| Funding Source: | NIH/NCI |
| Role: | Statistical Analyst |
| ID: | 1R01CA277995-01A1 |
| Date: | 2023 - 2028 |
| Title: | Extracellular non-coding RNAs as biomarkers for the early detection of lung cancers |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA280784-01 |
| Date: | 2023 - 2026 |
| Title: | Integrative modeling of spatially resolved multi-omics data to identify bladder cancer mucosal field effects |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP230166 |
| Date: | 2023 - 2026 |
| Title: | Therapeutic vulnerabilities and predictors of response to chemo(immuno)therapy in patients with high-risk, early stage triple-negative breast cancer (TNBC) |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP230134 |
| Date: | 2023 - 2026 |
| Title: | The evolution of intra-tumor heterogeneity of lung cancers with or without immunotherapy and its impact on patient survival |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RP230112 |
| Date: | 2023 - 2026 |
| Title: | Defining the optimal radiation beam and fractionation parameters for FLASH radiotherapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2023 - 2026 |
| Title: | Targeting Anti-Apoptotic Pathways in MDS at time of Progression |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Biostatistician |
| ID: | #TBA |
| Date: | 2023 - 2026 |
| Title: | RP230011 Characterizing clonal evolution in MDS patients with HMA failure using longitudinal sequencing data and novel computational methods |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP230011 |
| Date: | 2023 - 2026 |
| Title: | Targeting Immune-checkpoint Protein B7-H3 in Breast Cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Biostatistician |
| ID: | #TBA |
| Date: | 2023 - 2026 |
| Title: | RP230339 Determination of regulatory mechanisms involved in the Tumor Microenvironment using eXplainable Artificial Intelligence |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Bioinformatics |
| ID: | RP230339 |
| Date: | 2023 - 2026 |
| Title: | Ferroptosis-based Therapy in Acute Myeloid Leukemia |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Biostatistician |
| ID: | RP230355 |
| Date: | 2023 - 2028 |
| Title: | Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| ID: | 1R01CA270010-01A1 |
| Date: | 2023 - 2025 |
| Title: | Aerosol Gemcitabine to enhance NK cell therapy against Osteosarcoma |
| Funding Source: | Children's Cancer Research Fund |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2023 - 2023 |
| Title: | Pinpointing the CCR7+ dendritic cells on the tumor map |
| Funding Source: | American Association of Immunologists |
| Role: | Co-PI |
| ID: | #TBA |
| Date: | 2023 - 2025 |
| Title: | Delineating Single-cell Level Intra-tumoral Heterogeneity and Validating Its Association with Chemoradiation Responses in Esophageal Adenocarcinoma |
| Funding Source: | DeGregorio Foundation |
| Role: | Biostatistician |
| ID: | FP18082 |
| Date: | 2023 - 2023 |
| Title: | Targeting Immune-Checkpoint Protein B7-H3 (CD276) in Breast Cancer |
| Funding Source: | Elsa U Pardee Foundation |
| Role: | Biostatistician |
| ID: | #TBA |
| Date: | 2022 - 2024 |
| Title: | Targeting MerTK using novel antibody drug conjugate RGX-019 in AML |
| Funding Source: | Inspirna |
| Role: | Biostatistician |
| ID: | LS2023-00061796-JW |
| Date: | 2022 - 2027 |
| Title: | Statistical and machine learning methods for deciphering single cell signals from myelodysplastic syndromes |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA275854-01 |
| Date: | 2022 - 2027 |
| Title: | Nanoengineered genome editing for cancer therapy |
| Funding Source: | NIH/NCI |
| Role: | Statistical Analyst |
| ID: | 1R01CA277995-01 |
| Date: | 2022 - 2027 |
| Title: | The evolution of intri-tumor heterogeneity of lung cancers with or without immunotherapy and its impact on patient survival |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA269469-01A1 |
| Date: | 2022 - 2023 |
| Title: | Targeting CD47-SIRPα Interactions in Acute Myeloid Leukemia |
| Funding Source: | Elsa U Pardee Foundation |
| Role: | Biostatistician |
| ID: | #TBA |
| Date: | 2022 - 2027 |
| Title: | Specialized Center of Research: An Integrated Approach towards Improving Outcomes in Higher Risk Myelodysplastic Syndromes |
| Funding Source: | Leukemia and Lymphoma Society |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2022 - 2025 |
| Title: | Targeting Immunologically Primed Esophageal Adenocarcinoma for Organ-Sparing Approaches |
| Funding Source: | DeGregorio Foundation |
| Role: | Biostatistician |
| ID: | #TBA |
| Date: | 2022 - 2027 |
| Title: | Acquired Resistance to Therapy and Iron (ARTI) Center – Project 3 |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| ID: | 1U54CA274220-01 |
| Date: | 2022 - 2027 |
| Title: | Acquired Resistance to Therapy and Iron (ARTI) Center-Admin Core |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| ID: | 1U54CA274220-01 |
| Date: | 2022 - 2027 |
| Title: | Coordinating and Data Management Center for Translational and Basic Science Research in Early Lesions |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1U24CA274212-01 |
| Date: | 2022 - 2027 |
| Title: | Preclinical optimization of ultra-high dose rate (FLASH) radiotherapy parameters for translational relevance |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA266673-01A1 |
| Date: | 2022 - 2023 |
| Title: | Induced Pluripotent Stem Cells-derived NK Cells for AML Therapy |
| Funding Source: | FATE Therapeutics, INC |
| Role: | Biostatistician |
| ID: | LS2022-00061189-RP |
| Date: | 2022 - 2025 |
| Title: | Intratumoral Reprogramming and Accumulation of Regulatory T Cells: A New Magic Bullet to Fight Cancer |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2022 - 2027 |
| Title: | CLINICAL VALIDATION OF PREDICTIVE BIOMARKERS OF RESPONSE TO VENETOCLAX-BASED THERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AT THE TIME OF PROGRESSION AFTER THERAPY WITH HYPOMETHYLATING AGENTS |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1R01CA276567-01 |
| Date: | 2022 - 2027 |
| Title: | Alternative transcript synthesis in medulloblastoma |
| Funding Source: | NIH/NINDS |
| Role: | Biostatistician |
| ID: | 1R01NS129767-01 |
| Date: | 2022 - 2027 |
| Title: | New Approach for Osteosarcoma: Enhancing and Monitoring NK Cell Therapy |
| Funding Source: | NIH/NCI |
| Role: | Bioinformatician |
| ID: | 1P01CA275719-01 |
| Date: | 2022 - 2025 |
| Title: | Targeting Immune-checkpoint Protein B7-H3 in Breast Cancer Using a Novel Blocking Antibody |
| Funding Source: | US Department of Defense |
| Role: | Biostatistician |
| ID: | #TBA |
| Date: | 2022 - 2025 |
| Title: | RA210043 Metabolic and immune microenvironmental regulation in adrenocortical carcinoma |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2022 - 2027 |
| Title: | Investigating the Checkpoint Protein B7-H3 in Breast Cancer Immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | Statistician |
| ID: | 1R01CA272741-01 |
| Date: | 2022 - 2024 |
| Title: | Characterization of the lymphoma microenvironment and its effect on response and toxicity following low-dose radiation and CAR T-cell therapy in patients with relapsed/refractory follicular lymphoma |
| Funding Source: | The Follicular Lymphoma Foundation |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2022 - 2027 |
| Title: | Innovative Nanotechnology for Cancer Epigenome Editing |
| Funding Source: | NIH/NCI |
| Role: | Statistical Analyst |
| ID: | 1R01CA274418-01 |
| Date: | 2022 - 2027 |
| Title: | Therapeutics aptamers for SARS-CoV-2 treatment |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01AI167288-01A1 |
| Date: | 2022 - 2024 |
| Title: | Methods and tools for predicting eGFR decline in individual ADPKD patients |
| Funding Source: | NIH/NDDK subaward via Emory University |
| Role: | PD/PI |
| ID: | 1 R21 DK131411-01A1 |
| Date: | 2022 - 2027 |
| Title: | MD Anderson SPORE in Brain Metastasis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1P50CA272300-01 |
| Date: | 2022 - 2027 |
| Title: | MD Anderson SPORE in KRASG12C |
| Funding Source: | NIH/NCI |
| Role: | Biostatistics and Bionformatics Core Co-Investigator |
| ID: | 1P50CA261607-01A1 |
| Date: | 2022 - 2025 |
| Title: | Phase I Study of Aerosol Gemcitabine in Patients with Solid Tumors and Pulmonary Metastases study |
| Funding Source: | Gateway for Cancer Research |
| Role: | Collaborator |
| ID: | #TBA |
| Date: | 2022 - 2024 |
| Title: | Defining the role of BRD4 and G9a in chemotherapy-induced autophagy in Osteosarcoma |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 1R21CA273982-01 |
| Date: | 2022 - 2024 |
| Title: | Standardization of husbandry practices in Xenopus laevis using the corticosterone stress response |
| Funding Source: | American Association for Laboratory Animal Science |
| Role: | Professional |
| ID: | #TBA |
| Date: | 2022 - 2025 |
| Title: | Statistical models for intratumor heterogeneity of tumor-infiltrated leukocytes in lung cancer |
| Funding Source: | NIH/NCI |
| Role: | PD/PI |
| ID: | 1R03CA270725-01 |
| Date: | 2022 - 2024 |
| Title: | Delineating Single Cell Level Intra-Tumoral Heterogeneity and Validating It's Association with Chemoradiation Responses in Esophageal Adenocarcinoma |
| Funding Source: | US Department of Defense |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2022 - 2027 |
| Title: | Role of C5aR1 Signaling in Glioma Progression |
| Funding Source: | NIH/NINDS |
| Role: | Co-I |
| ID: | 1R01NS126472-01 |
| Date: | 2022 - 2024 |
| Title: | Targeting vulnerabilities in mitochondrial energy metabolism in metastatic uveal melanoma: effect on tumor growth and metabolic profile |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R21CA270995-01 |
| Date: | 2022 - 2025 |
| Title: | Novel Anti-B7-H3 Antibody-based Immunotherapy for Acute Myeloid Leukemia |
| Funding Source: | Siddhi Therapeutics, Inc |
| Role: | Biostatistician |
| ID: | #TBA |
| Date: | 2022 - 2027 |
| Title: | Investigating the Role of Gangliosides GD2 and GD3 in Triple-negative Breast Cancer Progression |
| Funding Source: | NIH/NCI |
| Role: | Statistician |
| ID: | 1R01CA269833-01 |
| Date: | 2022 - 2025 |
| Title: | Targeting Anti-Apoptotic Pathways in MDS Patients with Refractory Disease |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Other professional |
| ID: | #TBA |
| Date: | 2022 - 2025 |
| Title: | Integrative modeling of spatially resolved multi-omics data to identify bladder cancer mucosal field effects (108) |
| Funding Source: | Cancer Prevention Research Inst of TX |
| Role: | Co-I |
| ID: | RP220132 |
| Date: | 2022 - 2024 |
| Title: | Targeting SIRPα to Prevent Recurrence of Acute Myeloid Leukemia |
| Funding Source: | PREVENT CANCER FOUNDATION (PCF) |
| Role: | Biostatistician |
| ID: | #TBA |
| Date: | 2021 - 2023 |
| Title: | Targeting CD47-SIRPα Interactions in Acute Myeloid Leukemia |
| Funding Source: | Emerson Collective |
| Role: | Statistician |
| ID: | #TBA |
| Date: | 2021 - 2023 |
| Title: | Characterizing the Cooperation between TET2 Deficiency and KDM6B in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia: Pathogenic Mechanisms and Therapeutic Potential |
| Funding Source: | Dresner Foundation |
| Role: | Bioinformatician |
| ID: | #TBA |
| Date: | 2021 - 2027 |
| Title: | Integrating patient-specific clinical and biological factors towards individualizing utilization of proton and photon radiation therapy – Project 2 |
| Funding Source: | NIH/NCI |
| Role: | Collaborator |
| ID: | 5P01CA261669-02 |
| Date: | 2021 - 2023 |
| Title: | MDS/AML Moonshot |
| Funding Source: | MD Anderson Moonshot Program |
| Role: | Biostatistician |
| ID: | 710499-80-123137-123138-21 |
| Date: | 2021 - 2026 |
| Title: | Modulation of Neuroimmune Pathways by WWOX: Implications for Complex Brain Disorders |
| Funding Source: | NIH/NIMH |
| Role: | Collaborator |
| ID: | 1R01MH128215-01 |
| Date: | 2021 - 2023 |
| Title: | Methods and tools for predicting eGFR decline in individual ADPKD patients |
| Funding Source: | NIH/NCI subaward via Emory University |
| Role: | Principal Investigator-MDACC |
| ID: | #TBA |
| Date: | 2021 - 2025 |
| Title: | A Novel Hsp90 Inhibitor as a Chemo and Radiosensitizer in Adults with Glioblastoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5R01CA235673-04 |
| Date: | 2021 - 2022 |
| Title: | Risk Factors and Mechanisms of Radiation Induced Cardiovascular Disease |
| Funding Source: | MDACC Multidisciplinary Research Program (MRP) |
| Role: | Biostatistician |
| ID: | 600661-30-123898-28 |
| Date: | 2021 - 2023 |
| Title: | Improving prediction of TCR-epitope pairs using pMTnet in combination with novel validation approaches |
| Funding Source: | Foundation For The Natl Institute Of Health |
| Role: | Co-I |
| ID: | #TBA |
| Date: | 2021 - 2022 |
| Title: | Standardization of husbandry practices in Xenopus laevus using corticosterone stress response |
| Funding Source: | American Coll of Laboratory Animal Med |
| Role: | Biostatistician |
| ID: | #TBA |
| Date: | 2020 - 2022 |
| Title: | Breast Cancer Moonshot Project 2 |
| Funding Source: | MDACC Moonshots Program |
| Role: | Biostatistician |
| ID: | 710499-80-123093-21 |
| Date: | 2020 - 2022 |
| Title: | Microsimulation Modeling to Evaluate the Clinical Effectiveness of Novel Cancer Therapies |
| Funding Source: | Burroughs Wellcome Fund |
| Role: | Co-I |
| ID: | 1016433.01 |
| Date: | 2019 - 2024 |
| Title: | SPORE in Brain Cancer - BIOSTATISTICS AND BIOINFORMATICS CORE (CORE C) |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| ID: | 5P50CA127001-12 |
| Date: | 2019 - 2025 |
| Title: | Recruitment of Established Investigators |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RR190079 |
| Date: | 2019 - 2024 |
| Title: | Cancer Center Support grant - Biostatistics Resource Group (BRG) |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| ID: | 5P30CA016672-46 |
| Date: | 2019 - 2022 |
| Title: | Targeting Hypomethylating Resistance in Myelodysplastic Syndromes |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Biostatistician |
| ID: | RP190295 |
| Date: | 2018 - 2023 |
| Title: | Validation of Critical 1q21 Vulnerabilities in Multiple Myeloma |
| Funding Source: | NIH/NCI |
| Role: | Biostatistician |
| ID: | 5R01CA222253-05 |
Selected Publications
Peer-Reviewed Articles
- Nath, S, Qdaisat, AZ, Derkach, A, Babar, A, Zalavadia, D, Chaftari, P, Li, Z, Wattana, M, Schmeltz, J, Johnston, RP, Ortiz, EJ, Alagappan, K, Klotz, A, Yeung, SJ. Development and Validation of a Prognostic Risk Score for Patients With Cancer and Neutropenic Fever Presenting to the Emergency Department. JACEP Open 7(2), 2026. e-Pub 2026.
- Wang Y, Zang C, Li Z, Guo CC, Lai D, Wei P. A comparative study of statistical methods for identifying differentially expressed genes in spatial transcriptomics. PLoS Comput Biol 22(2):e1013956, 2026. e-Pub 2026. PMID: 41671295.
- Waldrop, T, Murley, GA, Velasquez, B, Konradsson, E, Neill, D, Connell, L, Hernandez, AL, Delahoussaye, AM, Schuler, FW, La Cerda, JD, Li, Z, Pagel, MD, Schueler, E. Investigating the oxygen dependence of FLASH-RT using electron paramagnetic resonance imaging. Radiotherapy and Oncology 215, 2026. e-Pub 2026. PMID: 41389858.
- Kumar, S, Pelster, MS, Hasanov, M, Guerrieri, R, Hudgens, CW, Ledesma, D, Wang, F, Fischer, G, Simon, JM, Haydu, LE, Katlowitz, KV, Yennu Nanda, VG, McQuade, JL, Kwong, L, Huse, J, Lazar, A, Tetzlaff, M, Gershenwald, JE, Joon, A, Chen, K, Li, Z, Ram, P, Ferguson, SD, Davies, MA. Integrated analysis of molecular and clinical features associated with overall survival in melanoma patients with brain metastasis. Acta Neuropathologica Communications 13(1), 2025. e-Pub 2025. PMID: 40229864.
- Brock, PA, Langabeer, DM, Page, VD, Li, Z, Qdaisat, AZ. Impact of Boarding Time on In-Hospital Mortality in Patients Presenting to an Oncologic Emergency Department of a Comprehensive Cancer Center. JACEP Open 6(6), 2025. e-Pub 2025. PMID: 41140930.
- Ren, B, Li, R, Lin, CY, Park, C, Wang, S, Suen, A, Kessler, J, Yang, S, Kozar, RA, Zou, L, Williams, B, Li, Z, Hu, P, Chao, W. Nucleotide motif-guided selection of plasma microRNA biomarkers in trauma. iScience 28(10), 2025. e-Pub 2025. PMID: 41079605.
- Lin, SH, Subbiah, V, Cohen, E, Li, Z, Lu, YJ, Son, YL, Lyu, Y, Gao, H, Jayachandran, G, Neri, S, Sharma, A, Fang, PQ, Karp, DD, Hong, DS, Rodon Ahnert, J, Yu, H, Peng, J, Lloyd, GK, Tonra, JR, Reuben, JM, Huang, L, Fu, S. Plinabulin following radiation enhances dendritic cell maturation and checkpoint inhibitor retreatment of relapsed/refractory cancers. Med 6(10), 2025. e-Pub 2025. PMID: 40580957.
- Shui, L, Maitra, A, Yuan, Y, Lau, KS, Kaur, H, Li, L, Li, Z. PoweREST. PLoS computational biology 21(7), 2025. e-Pub 2025. PMID: 40729405.
- Liu, K, Titt, U, Esplen, NM, Connell, L, Konradsson, E, Yang, M, Wang, X, Takaoka, T, Li, Z, Koong, A, Mitra, D, Mohan, R, Loo, BW, Lin, SH, Schueler, E. Discordance in Acute Gastrointestinal Toxicity between Synchrotron-Based Proton and Linac-based Electron Ultra-High Dose Rate Irradiation. International Journal of Radiation Oncology Biology Physics 122(2):491-501, 2025. e-Pub 2025. PMID: 39862897.
- Nastoupil, L, Andersen, C, Ayers, AA, Wang, Y, Habermann, TM, Chihara, D, Kahl, BS, Link, BK, Koff, JL, Cohen, JB, Martin, P, Lossos, IS, Stanchina, M, Haddadi, S, Casulo, C, Ayyappan, S, Lin, R, Li, Z, Larson, MC, Maurer, MJ, Huynh, L, Gao, C, Ramasubramanian, R, Duh, MS, Mutebi, A, Wang, T, Jun, M, Wang, A, Kamalakar, R, Kalsekar, A, Cerhan, JR, Flowers, CR. Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia 25(4):e183-e199.e8, 2025. e-Pub 2025. PMID: 39966020.
- Liu, K, Waldrop, T, Aguilar, E, Mims, N, Neill, D, Delahoussaye, AM, Li, Z, Swanson, DM, Lin, SH, Koong, A, Taniguchi, C, Loo, BW, Mitra, D, Schueler, E. Redefining FLASH Radiation Therapy. International Journal of Radiation Oncology Biology Physics 121(4):1063-1076, 2025. e-Pub 2025. PMID: 39424078.
- Altan, M, Li, R, Li, Z, Chen, R, Sheshadri, A, Tran, HT, Little, L, Baguley, J, Sinson, JC, Vokes, N, Gandhi, S, Antonoff, MB, Swisher, SG, Lizee, GA, Reuben, A, Heymach, JV, Zhang, J. High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC. Journal for immunotherapy of cancer 12(12), 2024. e-Pub 2024. PMID: 39721752.
- Wang, Y, Dede, M, Mohanty, V, Dou, J, Li, Z, Chen, K. A statistical approach for systematic identification of transition cells from scRNA-seq data. Cell Reports Methods 4(12), 2024. e-Pub 2024. PMID: 39644902.
- Luo, L, Yang, P, Mastoraki, S, Rao, X, Wang, Y, Kettner, NM, Singareeka Raghavendra, A, Tripathy, D, Damodaran, S, Hunt, KK, Wang, J, Li, Z, Keyomarsi, K. Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancer. Molecular cancer 24(1), 2024. e-Pub 2024. PMID: 39955556.
- Qdaisat, AZ, Stroh, E, Reyes-Gibby, CC, Wattana, M, Viets-Upchurch, J, Li, Z, Page, VD, Fatima, H, Chaftari, P, Elsayem, A. Severity of Symptoms as an Independent Predictor of Poor Outcomes in Patients with Advanced Cancer Presenting to the Emergency Department. Cancers 16(23), 2024. e-Pub 2024. PMID: 39682175.
- Li, Z, Li, R, Ganan Gomez, I, Abbas, HA, Garcia-Manero, G, Sun, W. Accurate identification of locally aneuploid cells by incorporating cytogenetic information in single cell data analysis. Scientific reports 14(1), 2024. e-Pub 2024. PMID: 39406835.
- Saito, Y, Xiao, Y, Yao, J, Li, Y, Liu, W, Yuzhalin, A, Shyu, YM, Li, H, Yuan, X, Li, P, Zhang, Q, Li, Z, Wei, Y, Yin, X, Zhao, J, Kariminia, SM, Wu, Y, Wang, J, Yang, JX, Xia, W, Sun, Y, Jho, EH, Chiao, PJ, Hwang, RF, Ying, H, Wang, H, Zhao, Z, Maitra, A, Hung, MC, DePinho, RA, Yu, D. Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer. Cell Discovery 10(1), 2024. e-Pub 2024. PMID: 39468013.
- Anfossi, S, Darbaniyan, F, Quinlan, J, Calin, S, Shimizu, M, Chen, M, Rausseo, P, Winters, M, Bogatenkova, E, Do, K, Martinez, I, Li, Z, Antal, L, Olariu, TR, Wistuba, II, Calin, GA. MicroRNAs are enriched at COVID-19 genomic risk regions, and their blood levels correlate with the COVID-19 prognosis of cancer patients infected by SARS-CoV-2. Molecular cancer 23(1), 2024. e-Pub 2024. PMID: 39434078.
- Lyu Y, Lin SH, Wu H, Li Z. SCIntRuler: Guiding the integration of multiple single-cell RNA-seq datasets with a novel statistical metric. Bioinformatics 40(9), 2024. e-Pub 2024. PMID: 39226185.
- Yang, P, Hubert, SM, Futreal, PA, Song, X, Zhang, J, Lee, JJ, Wistuba, II, Yuan, Y, Zhang, J, Li, Z. A Novel Bayesian Model For Assessing Intratumor Heterogeneity Of Tumor Infiltrating Leukocytes With Multiregion Gene Expression Sequencing. Annals of Applied Statistics 18(3):1879-1898, 2024. e-Pub 2024.
- Wei Y, Zheng H, Li Z, Lockyer PP, Darbaniyan F, Kanagal-Shamanna R, Yang H, Hammond D, Garcia-Manero G. Downregulation of UBA1 expression in myelodysplastic neoplasm. Leukemia 38(10):2284-2288, 2024. e-Pub 2024. PMID: 39179668.
- Sui Z, Li Z, Sun W. Exploit Spatially Resolved Transcriptomic Data to Infer Cellular Features from Pathology Imaging Data. bioRxiv, 2024. e-Pub 2024. PMID: 39149252.
- Wattana MK, Lindsay A, Davenport M, Pettit NR, Menendez JR, Li Z, Lipe DN, Qdaisat A, Bischof JJ. Current gaps in emergency medicine core content education for oncologic emergencies: A targeted needs assessment. AEM Educ Train 8(3):e10987, 2024. e-Pub 2024. PMID: 38765712.
- Wang Y, Flowers CR, Wang M, Huang X, Li Z. CASi: A framework for cross-timepoint analysis of single-cell RNA sequencing data. Sci Rep 14(1):10633, 2024. e-Pub 2024. PMID: 38724550.
- Bazinet A, Desikan SP, Li Z, Rodriguez-Sevilla JJ, Venugopal S, Urrutia S, Montalban-Bravo G, Sasaki K, Chien KS, Hammond D, Kanagal-Shamanna R, Ganan-Gomez I, Kadia TM, Borthakur G, DiNardo CD, Daver NG, Jabbour EJ, Ravandi F, Kantarjian H, Garcia-Manero G. Cytogenetic and molecular associations with outcomes in HR-MDS treated with hypomethylating agents plus venetoclax. Clin Cancer Res 30(7):1319-1326, 2024. e-Pub 2024. PMID: 38300723.
- Akiyama H, Zhao R, Ostermann LB, Li Z, Tcheng M, Yazdani SJ, Moayed A, Pryor ML, Slngh S, Baran N, Ayoub E, Nishida Y, Mak PY, Ruvolo VR, Carter BZ, Schimmer AD, Andreeff M, Ishizawa J. Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia. Leukemia 38(4):729-740, 2024. e-Pub 2023. PMID: 38148395.
- Akiyama H, Zhao R, Ostermann LB, Li Z, Tcheng M, Yazdani SJ, Moayed A, Pryor ML, Slngh S, Baran N, Ayoub E, Nishida Y, Mak PY, Ruvolo VR, Carter BZ, Schimmer AD, Andreeff M, Ishizawa J. Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia. Leukemia 38(4):926, 2024. e-Pub 2024. PMID: 38459170.
- Lyu Y, Wu C, Sun W, Li Z. Regional analysis to delineate intrasample heterogeneity with RegionalST. Bioinformatics 40(4), 2024. e-Pub 2024. PMID: 38579257.
- Chi S, Flowers CR, Li Z, Huang X, Wei P. MASH: MEDIATION ANALYSIS OF SURVIVAL OUTCOME AND HIGH-DIMENSIONAL OMICS MEDIATORS WITH APPLICATION TO COMPLEX DISEASES. Annals Of Appl Stat, 2024. e-Pub 2024. PMID: 37662296.
- Chien KS, Ong F, Kim K, Li Z, Kanagal-Shamanna R, DiNardo CD, Takahashi K, Montalban-Bravo G, Hammond D, Sasaki K, Pierce SA, Kantarjian HM, Garcia-Manero G. Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms. Cancer Med 13(5):e7093, 2024. e-Pub 2024. PMID: 38497538.
- El-Badry, E, Chen, L, Ghneim, K, Li, Z, Brooks, K, Rhodes, J, Sekaly, RP, Kilembe, W, Allen, S, Wu, H, Hunter, E. Heightened expression of type I interferon signaling genes in CD4+ T cells from acutely HIV-1–infected women is associated with lower viral loads. Frontiers in immunology 15, 2024. e-Pub 2024. PMID: 39902043.
- Li Z, Yang P. Inferring Novel Cells in Single-Cell RNA-Sequencing Data. Methods Mol Biol 2812:143-154, 2024. e-Pub 2024. PMID: 39068360.
- Montalban-Bravo G, Kanagal-Shamanna R, Li Z, Hammond D, Chien K, Rodriguez-Sevilla JJ, Sasaki K, Jabbour E, DiNardo C, Takahashi K, Short N, Issa GC, Pemmaraju N, Kadia T, Ravandi F, Daver N, Borthakur G, Loghavi S, Pierce S, Bueso-Ramos C, Kantarjian H, Garcia-Manero G. Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia. Br J Haematol 203(4):581-592, 2023. e-Pub 2023. PMID: 37608562.
- Urrutia S, Chien KS, Li Z, Bataller A, Almanza E, Sasaki K, Montalban-Bravo G, Short NJ, Jabbour E, Kadia TM, Ravandi F, Borthakur G, Alvarado Y, Daver N, Kanagal-Shamanna R, Bueso-Ramos C, Pierce SA, Kantarjian H, Garcia-Manero G. Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failure. Am J Hematol 98(10):E281-E284, 2023. e-Pub 2023. PMID: 37515433.
- Aaroe A, Kurzrock R, Goyal G, Goodman AM, Patel H, Ruan GJ, Ulaner G, Young JR, Li Z, Dustin D, Go RS, Diamond EL, Janku F. Successful Treatment of Non-Langerhans Cell Histiocytosis with the MEK Inhibitor Trametinib: A Multicenter Analysis. Blood Adv 7(15):3984-3992, 2023. e-Pub 2023. PMID: 36857436.
- Feng H, Meng G, Lin T, Parikh H, Pan Y, Li Z, Krischer J, Li Q. ISLET: individual-specific reference panel recovery improves cell-type-specific inference. Genome Biol 24(1):174, 2023. e-Pub 2023. PMID: 37496087.
- Li R, Altan M, Reuben A, Lin R, Heymach JV, Tran H, Chen R, Little L, Hubert S, Zhang J, Li Z. A novel statistical method for decontaminating T-cell receptor sequencing data. Brief Bioinform 24(4), 2023. e-Pub 2023. PMID: 37337757.
- Dragomir MP, Fuentes-Mattei E, Winkle M, Okubo K, Bayraktar R, Knutsen E, Qdaisat A, Chen M, Li Y, Shimizu M, Pang L, Liu K, Liu X, Anfossi S, Zhang H, Koch I, Tran AM, Mohapatra S, Ton A, Kaplan M, Anderson MW, Rothfuss SJ, Silasi R, Keshari RS, Ferracin M, Ivan C, Rodriguez-Aguayo C, Lopez-Berestein G, Georgescu C, Banerjee PP, Basar R, Li Z, Horst D, Vasilescu C, Bertilaccio MTS, Rezvani K, Lupu F, Yeung SC, Calin GA. Anti-miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response. J Clin Invest 133(14), 2023. e-Pub 2023. PMID: 37261908.
- Li Z, Shen Y, Ning J. Accommodating time-varying heterogeneity in risk estimation under the Cox model: a transfer learning approach. Journal of the American Statistical Association:1-19, 2023. e-Pub 2023. PMID: 38505403.
- Suen AO, Chen F, Wang S, Li Z, Zhu J, Yang Y, Conn O, Lopez K, Cui P, Wechsler L, Cross A, Fiskum G, Kozar R, Hu P, Miller C, Zou L, Williams B, Chao W. Extracellular RNA Sensing Mediates Inflammation and Organ Injury in a Murine Model of Polytrauma. J Immunol 210(12):1990-2000, 2023. e-Pub 2023. PMID: 37133342.
- Urrutia S, Li Z, Almanza E, Bataller A, Kanagal-Shamanna R, Senapati J, Sasaki K, Chien K, Montalban-Bravo G, DiNardo C, Borthakur G, Bueso-Ramos C, Pierce S, Kantarjian H, Garcia-Manero G. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations. Leukemia 37(6):1397-1400, 2023. e-Pub 2023. PMID: 37185307.
- Li Z, Huang Y, Patil D, Rubin M, Sanda MG. Covariate-specific evaluation of continuous biomarker. Stat Med 42(7):953-969, 2023. e-Pub 2023. PMID: 36600184.
- Abbas HA, Sun H, Pierce SR, Kanagal-Shamanna R, Li Z, Yilmaz M, Borthakur G, DiPippo AJ, Jabbour EJ, Konopleva MY, Short NJ, DiNardo CD, Daver NG, Ravandi F, Kadia TM. Validation of Acute Leukemia French Association ALFA1200 model in older patients with AML treated with intensive chemotherapy. Blood Adv 7(5):828-831, 2023. e-Pub 2022. PMID: 35405739.
- Ding W, Fischer L, Chen Q, Li Z, Yang L, You Z, Hu K, Wu X, Zhou X, Chao W, Hu P, Dagnew TM, DuBreuil DM, Wang S, Xia S, Bao C, Zhu S, Chen L, Wang C, Wainger B, Jin P, Mao J, Feng G, Harnett MT, Shen S. Highly synchronized cortical circuit dynamics mediate spontaneous pain in mice. J Clin Invest 133(5), 2023. e-Pub 2023. PMID: 36602876.
- Li Z, Huang Y, Patil D, Sanda MG. Covariate adjustment in continuous biomarker assessment. Biometrics 79(1):39-48, 2023. e-Pub 2021. PMID: 34811731.
- Chen L, Li Z, Wu H. CeDAR: incorporating cell type hierarchy improves cell type-specific differential analyses in bulk omics data. Genome Biol 24(1):37, 2023. e-Pub 2023. PMID: 36855165.
- Liu K, Palmiero A, Chopra N, Velasquez B, Li Z, Beddar S, Schüler E. Dual beam-current transformer design for monitoring and reporting of electron ultra-high dose rate (FLASH) beam parameters. J Appl Clin Med Phys 24(2):e13891, 2023. e-Pub 2023. PMID: 36601691.
- Meng G, Tang W, Huang E, Li Z, Feng H. A comprehensive assessment of cell type-specific differential expression methods in bulk data. Brief Bioinform 24(1), 2023. e-Pub 2023. PMID: 36472568.
- Li R, Zhang J, Li Z. EasyCellType: marker-based cell-type annotation by automatically querying multiple databases. Bioinform Adv 3(1):vbad029, 2023. e-Pub 2023. PMID: 36998720.
- Wei Y, Zheng H, Lockyer PP, Darbaniyan F, Li Z, Kanagal-Shamanna R, Soltysiak KA, Yang H, Ganan-Gomez I, Montalban-Bravo G, Chien KS, Do KA, Daver N, Garcia-Manero G. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 63(13):1-11, 2022. e-Pub 2022. PMID: 36059252.
- Abbas HA, Ayoub E, Sun H, Kanagal-Shamanna R, Short NJ, Issa G, Yilmaz M, Pierce S, Rivera D, Cham B, Wing S, Li Z, Hammond D, Jabbour E, Borthakur G, Garcia-Manero G, Andreeff M, Daver N, Kadia T, Konopleva M, DiNardo C, Ravandi F. Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of TP53 alterations and venetoclax treatment. Leuk Lymphoma 63(13):1-12, 2022. e-Pub 2022. PMID: 36089905.
- Liu Q, Zhang K, Kang Y, Li Y, Deng P, Li Y, Tian Y, Sun Q, Tang Y, Xu K, Zhou Y, Wang JL, Guo J, Li JD, Xia K, Meng Q, Allen EG, Wen Z, Li Z, Jiang H, Shen L, Duan R, Yao B, Tang B, Jin P, Pan Y. Expression of expanded GGC repeats within NOTCH2NLC causes behavioral deficits and neurodegeneration in a mouse model of neuronal intranuclear inclusion disease. Sci Adv 8(47):eadd6391, 2022. e-Pub 2022. PMID: 36417528.
- Li Z, Wang Y, Ganan-Gomez I, Colla S, Do KA. A machine learning-based method for automatically identifying novel cells in annotating single-cell RNA-seq data. Bioinformatics 38(21):4885-4892, 2022. e-Pub 2022. PMID: 36083008.
- Min, S, Xu, Q, Qin, L, Li, Y, Li, Z, Chen, C, Wu, H, Han, J, Zhu, X, Jin, P, Tang, B. Altered hydroxymethylome in the substantia nigra of Parkinson's disease. Human molecular genetics 31(20):3494-3503, 2022. e-Pub 2022. PMID: 35661211.
- Kim, K, Ong, F, Li, Z, Kanagal Shamanna, R, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G, Chien, KS. MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S313-S314, 2022. e-Pub 2022. PMID: 36163960.
- Chien, KS, Kim, K, Li, Z, Kanagal Shamanna, R, Ong, F, Montalban Bravo, G, Kadia, TM, Jabbour, EJ, Pemmaraju, N, Hammond, DE, Short, NJ, Ravandi-Kashani, F, Alvarado, Y, Pierce, S, Dong, XQ, Kantarjian, HM, Garcia-Manero, G. MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes. Clinical Lymphoma, Myeloma and Leukemia 22:S311, 2022. e-Pub 2022. PMID: 36163957.
- Min S, Xu Q, Qin L, Li Y, Li Z, Chen C, Wu H, Han J, Zhu X, Jin P. Altered hydroxymethylome in the substantia nigra of Parkinson's disease. Human Molecular Genetics 30(20):3494-3503, 2022. e-Pub 2022.
- Wang Y, Flowers CR, Li Z, Huang X. CondiS web app: imputation of censored lifetimes for machine learning-based survival analysis. Bioinformatics 38(17):4252-4254, 2022. e-Pub 2022. PMID: 35801895.
- Leung W, Teater M, Durmaz C, Meydan C, Chivu AG, Chadburn A, Rice EJ, Muley A, Camarillo JM, Arivalagan J, Li Z, Flowers CR, Kelleher NL, Danko CG, Imielinski M, Dave SS, Armstrong SA, Mason CE, Melnick AM. SETD2 haploinsufficiency enhances germinal center-associated AICDA somatic hypermutation to drive B cell lymphomagenesis. Cancer Discov 12(7):1782-1803, 2022. e-Pub 2022. PMID: 35443279.
- Wang Y, Flowers CR, Li Z, Huang X. CondiS: A conditional survival distribution-based method for censored data imputation overcoming the hurdle in machine learning-based survival analysis. J Biomed Inform 131:104117, 2022. e-Pub 2022. PMID: 35690348.
- Wei X, Li Z, Ji H, Wu H. EDClust: an EM-MM hybrid method for cell clustering in multiple-subject single-cell RNA sequencing. Bioinformatics 38(10):2692-2699, 2022. e-Pub 2022. PMID: 35561178.
- Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(5):1097, 2022. e-Pub 2022. PMID: 35484266.
- Duan D, He S, Huang E, Li Z, Feng H. NeuCA web server: a neural network-based cell annotation tool with web-app and GUI. Bioinformatics 38(8):2361-2363, 2022. e-Pub 2022. PMID: 35176143.
- Wang Y, Carter BZ, Li Z, Huang X. Application of machine learning methods in clinical trials for precision medicine. JAMIA Open 5(1):ooab107, 2022. e-Pub 2022. PMID: 35178503.
- Sun X, Lin X, Li Z, Wu H. A comprehensive comparison of supervised and unsupervised methods for cell type identification in single-cell RNA-seq. Brief Bioinform 23(2), 2022. e-Pub 2022. PMID: 35021202.
- Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nat Med 28(3):557-567, 2022. e-Pub 2022. PMID: 35241842.
- Qdaisat A, Yeung SJ, Rojas Hernandez CH, Samudrala P, Kamal M, Li Z, Wechsler AH. Characteristics and Outcomes of Intracranial Hemorrhage in Cancer Patients Visiting the Emergency Department. J Clin Med 11(3), 2022. e-Pub 2022. PMID: 35160096.
- Li Z, Feng H. A neural network-based method for exhaustive cell label assignment using single cell RNA-seq data. Sci Rep 12(1):910, 2022. e-Pub 2022. PMID: 35042860.
- Li Z, Jiang X, Wang Y, Kim Y. Applied machine learning in Alzheimer's disease research: omics, imaging, and clinical data. Emerg Top Life Sci 5(6):765-777, 2021. e-Pub 2021. PMID: 34881778.
- Wang S, Yang Y, Suen A, Zhu J, Williams B, Hu J, Chen F, Kozar R, Shen S, Li Z, Jeyaram A, Jay SM, Zou L, Chao W. Role of extracellular microRNA-146a-5p in host innate immunity and bacterial sepsis. iScience 24(12):103441, 2021. e-Pub 2021. PMID: 34877498.
- Zhang Q, Hu Q, Wang J, Miao Z, Li Z, Zhao Y, Wan B, Allen EG, Sun M, Jin P, Xu X. Stress modulates Ahi1-dependent nuclear localization of ten-eleven translocation protein 2. Hum Mol Genet 30(22):2149-2160, 2021. e-Pub 2021. PMID: 34218273.
- Meng C, Gu L, Li Y, Li R, Cao Y, Li Z, Allen EG, Zhu D, Jin P. Ten-eleven translocation 2 modulates allergic inflammation by 5-hydroxymethylcytosine remodeling of immunologic pathways. Hum Mol Genet 30(21):1985-1995, 2021. e-Pub 2021. PMID: 34165552.
- Kang Y, Zhou Y, Li Y, Han Y, Xu J, Niu W, Li Z, Liu S, Feng H, Huang W, Duan R, Xu T, Raj N, Zhang F, Dou J, Xu C, Wu H, Bassell GJ, Warren ST, Allen EG, Jin P, Wen Z. A human forebrain organoid model of fragile X syndrome exhibits altered neurogenesis and highlights new treatment strategies. Nat Neurosci 24(10):1377-1391, 2021. e-Pub 2021. PMID: 34413513.
- Mandel JJ, Youssef M, Yust-Katz S, Patel AJ, Jalali A, Li Z, Wu J, Ludmir EB, de Groot JF. IDH mutation status and the development of venous thromboembolism in astrocytoma patients. J Neurol Sci 427:117538, 2021. e-Pub 2021. PMID: 34146775.
- Chaftari P, Qdaisat A, Chaftari AM, Maamari J, Li Z, Lupu F, Raad I, Hachem R, Calin G, Yeung SJ. Prognostic Value of Procalcitonin, C-Reactive Protein, and Lactate Levels in Emergency Evaluation of Cancer Patients with Suspected Infection. Cancers (Basel) 13(16), 2021. e-Pub 2021. PMID: 34439240.
- Shelly KE, Candelaria NR, Li Z, Allen EG, Jin P, Nelson DL. Ectopic expression of CGG-repeats alters ovarian response to gonadotropins and leads to infertility in a murine FMR1 premutation model. Hum Mol Genet 30(10):923-938, 2021. e-Pub 2021. PMID: 33856019.
- Zhang W, Wu H, Li Z. Complete deconvolution of DNA methylation signals from complex tissues: a geometric approach. Bioinformatics 37(8):1052-1059, 2021. e-Pub 2021. PMID: 33135072.
- Kuehner JN, Chen J, Bruggeman EC, Wang F, Li Y, Xu C, McEachin ZT, Li Z, Chen L, Hales CM, Wen Z, Yang J, Yao B. 5-hydroxymethylcytosine is dynamically regulated during forebrain organoid development and aberrantly altered in Alzheimer's disease. Cell Rep 35(4):109042, 2021. e-Pub 2021. PMID: 33910000.
- Xu W, Zhang X, Liang F, Cao Y, Li Z, Qu W, Zhang J, Bi Y, Sun C, Zhang J, Sun B, Shu Q, Li X. Tet1 Regulates Astrocyte Development and Cognition of Mice Through Modulating GluA1. Front Cell Dev Biol 9:644375, 2021. e-Pub 2021. PMID: 34778243.
- Li Z, Chang C, Kundu S, Long Q. Bayesian generalized biclustering analysis via adaptive structured shrinkage. Biostatistics 21(3):610-624, 2020. e-Pub 2020. PMID: 30596887.
- Li Z, Guo Z, Cheng Y, Jin P, Wu H. Robust partial reference-free cell composition estimation from tissue expression. Bioinformatics 36(11):3431-3438, 2020. e-Pub 2020. PMID: 32167531.
- Zhang W, Li Z, Wei N, Wu HJ, Zheng X. Detection of differentially methylated CpG sites between tumor samples with uneven tumor purities. Bioinformatics 36(7):2017-2024, 2020. e-Pub 2020. PMID: 31769783.
- Qin L, Xu Q, Li Z, Chen L, Li Y, Yang N, Liu Z, Guo J, Shen L, Allen EG, Chen C, Ma C, Wu H, Zhu X, Jin P, Tang B. Ethnicity-specific and overlapping alterations of brain hydroxymethylome in Alzheimer's disease. Hum Mol Genet 29(1):149-158, 2020. e-Pub 2020. PMID: 31814020.
- Li Z, Wu Z, Jin P, Wu H. Dissecting differential signals in high-throughput data from complex tissues. Bioinformatics 35(20):3898-3905, 2019. e-Pub 2019. PMID: 30903684.
- Li Z, Wu H. TOAST: improving reference-free cell composition estimation by cross-cell type differential analysis. Genome Biol 20(1):190, 2019. e-Pub 2019. PMID: 31484546.
- Li Z, Roberts K, Jiang X, Long Q. Distributed learning from multiple EHR databases: Contextual embedding models for medical events. J Biomed Inform 92:103138, 2019. e-Pub 2019. PMID: 30825539.
- Cheng Y, Sun M, Chen L, Li Y, Lin L, Yao B, Li Z, Wang Z, Chen J, Miao Z, Xin N, Huang L, Allen EG, Wu H, Xu X, Jin P. Ten-Eleven Translocation Proteins Modulate the Response to Environmental Stress in Mice. Cell Rep 25(11):3194-3203.e4, 2018. e-Pub 2018. PMID: 30540950.
- Cheng Y, Li Z, Manupipatpong S, Lin L, Li X, Xu T, Jiang YH, Shu Q, Wu H, Jin P. 5-Hydroxymethylcytosine alterations in the human postmortem brains of autism spectrum disorder. Hum Mol Genet 27(17):2955-2964, 2018. e-Pub 2018. PMID: 29790956.
- Prout Parks E, Moore RH, Li Z, Bishop-Gilyard CT, Garrett AR, Hill DL, Bruton YP, Sarwer DB. Assessing the Feasibility of a Social Media to Promote Weight Management Engagement in Adolescents with Severe Obesity: Pilot Study. JMIR Res Protoc 7(3):e52, 2018. e-Pub 2018. PMID: 29555623.
- Hu YJ, Schmidt AF, Dudbridge F, Holmes MV, Brophy JM, Tragante V, Li Z, Liao P, Quyyumi AA, McCubrey RO, Horne BD, Hingorani AD, Asselbergs FW, Patel RS, Long Q, Consortium TG. Impact of Selection Bias on Estimation of Subsequent Event Risk. Circ Cardiovasc Genet 10(5), 2017. e-Pub 2017. PMID: 28986451.
- Li Z, Safo SE, Long Q. Incorporating biological information in sparse principal component analysis with application to genomic data. BMC Bioinformatics 18(1):332, 2017. e-Pub 2017. PMID: 28697740.
- Li L, Zang L, Zhang F, Chen J, Shen H, Shu L, Liang F, Feng C, Chen D, Tao H, Xu T, Li Z, Kang Y, Wu H, Tang L, Zhang P, Jin P, Shu Q, Li X. Fat mass and obesity-associated (FTO) protein regulates adult neurogenesis. Hum Mol Genet 26(13):2398-2411, 2017. e-Pub 2017. PMID: 28398475.
- Lal BK, Zhou W, Li Z, Kyriakides T, Matsumura J, Laderle FA, Freischlag J, Study Group OVAC. Predictors and outcomes of endoleaks in the Veterans Affairs Open Versus Endovascular Repair (OVER) trial of abdominal aortic aneurysms. Journal of vascular surgery 62(6):1394-1404, 2015. e-Pub 2015.
Review Articles
- Jurj A, Dragomir MP, Li Z, Calin GA. MicroRNAs in oncology: a translational perspective in the era of AI. Nat Rev Clin Oncol, 2026. e-Pub 2026. PMID: 41540122.
Other Articles
- Hoi, XP, Stangis, MM, Glass, SE, Kim, JH, Kang, SW, Brennen, WN, Li, Z, Grady, WM, Yegnasubramanian, S, Kuhn, P, Lyssiotis, CA, Sagara, A, Shrubsole, M, Kadara, HN, Yuan, Y, Coffey, RJ, Lau, KS, DeMarzo, AM, Maitra, A, Min, J, Yu, M, Chan, KS Cellular senescence in precancer lesions and early-stage cancers. Cancer cell 44(1):6-11, 2026. PMID: 41202812.
Abstracts
- Chien K, Kim K, Li Z, Shamanna RK, Ong F, Bravo GM, Kadia T, Jabbour E, Pemmaraju N, Hammond D, Short N. MDS-407 Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes. Clinical Lymphoma Myeloma and Leukemia(22):311, 2022. e-Pub 2022.
- Kim, K, Ong, F, Li, Z, Shamanna, RK, Bravo, GM, Kadia, T, Jabbour, E, Pemmaraju, N, Hammond, D, Short, N, Ravandi, F. MDS-431 Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes. Clinical Lymphoma Myeloma and Leukemia(22):S313-S314, 2022. e-Pub 2022.
Book Chapters
- Li, Z, Yang, P. Inferring Novel Cells in Single-Cell RNA-Sequencing Data. In: Transcriptome Data Analysis. Springer Nature, 143-154, 2024.
- Li Z, Wu H. Cell Type-Specific Analysis for High-throughput Data. In: Handbook of Statistical Bioinformatics. Springer, 2022.
Letters to the Editor
- Chien, KS, Braish, J, Li, Z, Loghavi, S, Bataller Torralba, A, Montalban Bravo, G, Sasaki, K, Kanagal Shamanna, R, Takahashi, K, DiNardo, C, Swaminathan, M, Kantarjian, HM, Garcia-Manero, G. Clinicopathologic characteristics and outcomes of patients with clonal hematopoiesis who progress to myeloid neoplasms. Leukemia 39: 1269-1272, 2025.
Patient Reviews
CV information above last modified March 31, 2026